Skip to main
ANIX

ANIX Stock Forecast & Price Target

ANIX Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anixa Biosciences is expected to showcase encouraging Phase 1 data from its breast cancer vaccine, which has shown positive immune responses in 74% of participants and generated top line revenues of $506,661 and $1,176,939 in 2020 and 2019 respectively. Additionally, its CAR-T program for ovarian cancer has also shown promising results, with top line revenues of $1,233,704 and $2,004,835 in 2020 and 2019 respectively, indicating potential for further growth and success in the future.

Bears say

Anixa Biosciences is an early-stage biotechnology company with promising but early data for its cancer prevention vaccine, and potential for durable treatment of ovarian cancer with its CAR-T therapy program. While the company's approaches are differentiated, the early stage of development and limited financial resources may present a high-risk investment opportunity.

ANIX has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anixa Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anixa Biosciences Inc (ANIX) Forecast

Analysts have given ANIX a Strong Buy based on their latest research and market trends.

According to 3 analysts, ANIX has a Strong Buy consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anixa Biosciences Inc (ANIX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.